← ORGANIGRAM GLOBAL INC.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net revenue | $80.4m | $86.8m | $79.2m | $145.8m | $161.6m | $159.8m | $259.2m | $274.2m | |
| Gross revenue (Note 20) | $97.5m | $103.4m | $109.9m | $209.1m | $233.6m | $247.2m | $403.0m | — | |
| Cost of sales (Note 7 and 21) | $42.5m |
$105.0m
+146.95%
|
$103.6m
-1.37%
|
$119.0m
+14.94%
|
$136.4m
+14.62%
|
$111.4m
-18.36%
|
$174.8m
+56.97%
|
— | |
| Gross margin before fair value adjustments | $37.9m | ($18.2m) | ($24.4m) | $26.8m | $25.2m | $48.5m | $84.3m | — | |
| Gross margin | $48.5m |
($56.5m)
-216.55%
|
($28.4m)
+49.73%
|
$31.6m
+211.16%
|
$38.0m
+20.36%
|
$47.5m
+25.08%
|
$90.2m
+89.83%
|
$97.7m
+8.30%
|
|
| Research and development | — | — | $3.6m | $6.0m | $13.2m | $11.2m | $10.9m | $10.0m | |
| Sales and marketing | $14.6m | $16.5m | $15.8m | $16.9m | $19.3m | $19.9m | $31.1m | — | |
| General and administrative (Note 23) | $18.6m | $28.0m | $33.6m | $42.9m | $53.0m | $45.9m | $59.5m | — | |
| Total operating expenses | $43.0m | $89.0m | $63.4m | $74.7m | $301.0m | $83.2m | $105.5m | $111.8m | |
| LOSS FROM OPERATIONS | $5.5m |
($145.5m)
-2751.90%
|
($91.8m)
+36.90%
|
($43.2m)
+53.00%
|
($263.0m)
-509.41%
|
($35.7m)
+86.44%
|
($15.3m)
+57.11%
|
||
| Investment income, net of financing costs | — | — | — | — | ($3.7m) | ($3.3m) | ($1.1m) | — | |
| Other non-operating income | — | — | — | — | ($548k) | ($176k) | ($142k) | — | |
| NET LOSS | ($9.5m) | ($136.2m) | ($130.7m) | ($14.3m) | ($248.6m) | ($45.4m) | ($24.8m) | ||
| Net loss per common share, basic (in CAD per share) | ($0) | ($1) | ($1) | ($0) | ($3) | ($0) | ($0) | — | |
| Net loss per common share, diluted (in CAD per share) | ($0) | ($1) | ($1) | ($0) | ($3) | ($0) | ($0) | — | |
| Change in fair value of derivative liabilities, preferred shares and other financial assets (Note 11, 12 and 13) | — | — | — | — | ($4.4m) | $7.7m | $27.5m | — | |
| Share issuance costs allocated to derivative liabilities and preferred shares (Note 14) | — | — | — | — | $0 | $937k | $170k | — | |
| Excise taxes | ($17.1m) | ($16.6m) | ($30.7m) | ($63.3m) | ($72.0m) | ($87.3m) | ($143.8m) | $149.8m | |
| Realized fair value on inventories sold and other inventory charges (Note 7) | — | — | ($35.7m) | ($35.2m) | ($56.2m) | ($52.1m) | ($67.1m) | — | |
| Unrealized gain on changes in fair value of biological assets (Note 6) | — | — | $31.7m | $40.0m | $69.0m | $51.2m | $73.0m | — | |
| Share-based compensation (Note 14 (iv)) | $9.2m | $4.7m | $3.2m | $4.7m | $5.3m | $6.3m | $4.0m | — | |
| Acquisition and transaction costs | — | — | — | — | — | $915k | $6.6m | — | |
| Share of loss from investments in associates | $1.3m | $1.2m | $1.1m | $1.4m | $1.0m | $5.3m | $0 | — | |
| Loss (gain) on disposal of property, plant and equipment and intangible assets | $613k | $39.8m | $2.4m | $6.6m | $418k | ($633k) | $9k | — | |
| Change in fair value of contingent consideration (Note 26) | $145k | ($886k) | $3.6m | ($2.6m) | ($3.4m) | ($50k) | ($9.7m) | — | |
| Loss before tax | ($5.9m) | ($146.6m) | ($130.7m) | ($14.4m) | ($252.4m) | ($45.4m) | ($38.5m) | — | |
| Deferred, net | — | ($10.5m) | $0 | ($488k) | ($3.6m) | $0 | ($13.8m) | — | |
| Change in fair value of investments at fair value through other comprehensive income (Note 11) | — | — | — | $0 | ($159k) | $96k | $666k | — | |
| COMPREHENSIVE LOSS | ($9.6m) | ($136.1m) | ($130.8m) | ($14.3m) | ($248.8m) | ($45.3m) | ($24.1m) |